A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.
January 2023 AbbVie Inc. Company Confidential
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.